在哈萨克斯坦人口中,遗传多态与妊娠糖尿病的关联:一个病例对照研究
Laura Danyarova1, Gulnara Svyatova2, Galina Berezina3
1National Center of Endocrinology and Diabetes, JSC Research Institute of Cardiology and Internal Diseases, Almaty 050012, Kazakhstan.
Diagnostics (Basel, Switzerland)
|March 14, 2026
概括
遗传因素对哈萨克妇女个体妊娠期糖尿病 (GDM) 风险没有很大的影响. 相反,适度的多基因架构和潜在的基因相互作用可能在GDM易感性中起作用.
科学领域:
- 遗传学和基因组学 遗传学和基因组学
- 生殖健康 生殖健康
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 孕期糖尿病 (GDM) 是一个日益严重的全球健康问题,患病率和相关的孕产妇和后代风险日益增加.
- 在GDM中承认遗传倾向,但其在哈萨克族人口中的作用仍未得到充分研究.
- 了解遗传因素对于识别有风险的个体和制定有针对性的干预措施至关重要.
研究的目的:
- 在哈萨克妇女中调查与β细胞功能和GDM风险相关的候选基因中选择的单核酸多态 (SNP) 之间的关联.
- 探索潜在的基因-基因相互作用影响GDM易感性在这个队列.
主要方法:
- 一项涉及365名哈萨克斯坦孕妇的病例控制研究 (217例GDM病例,148例对照).
- 八个与GDM或葡萄糖代谢相关的候选SNP的基因定型.
- 对SNP-GDM关联和基因与基因相互作用的多因素维度减小 (MDR) 的后勤回归分析.
主要成果:
- 单变量分析表明MTNR1B rs10830963 C等位基因具有保护作用,但在多变量调整和多次测试校正后,这并不显著.
- 在调整后的分析中,TCF7L2 rs7903146显示出显著的关联,但在FDR调整后失去意义.
- 在MDR分析中发现了显著的双位点 (IGF2BP2 rs4402960和CDKAL1 rs7754840) 和三位点 (IGF2BP2 rs4402960,MTNR1B rs10830963和PPARG rs1801282) 相互作用模型,尽管预测准确性有限.
结论:
- 在IGF2BP2,CDKAL1,MTNR1B,TCF7L2,PPARG和GCK中常见的变异可能不会在哈萨克族女性中产生强烈的个人GDM风险.
- 这些发现表明,多基因模型具有小效应尺寸和潜在的弱基因相互作用,有助于GDM易感性.
- 鉴定的相互作用模型需要进一步验证,因为它们的探索性质和有限的预测能力.
相关概念视频
Pathophysiology of Diabetes
4.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.1K
Principles of Pharmacogenetics: Types of Genetic Variants
72
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
72
Diabetes Mellitus: Type 2 and Gestational
5.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.3K
Genome-wide Association Studies-GWAS
16.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.4K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
93
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
93
Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73


